Potential for improvement of docetaxel-based chemotherapy: a pharmacological review.
about
Synergistic antitumor activities of docetaxel and octreotide associated with apoptotic-upregulation in castration-resistant prostate cancerMR-guided pulsed high intensity focused ultrasound enhancement of docetaxel combined with radiotherapy for prostate cancer treatment.Pharmacokinetic analysis of two different docetaxel dose levels in patients with non-small cell lung cancer treated with docetaxel as monotherapy or with concurrent radiotherapy.Co-administration of piperine and docetaxel results in improved anti-tumor efficacy via inhibition of CYP3A4 activitySkeletal muscle atrophy is attenuated in tumor-bearing mice under chemotherapy by treatment with fish oil and selenium.Knockout of cytochrome P450 3A yields new mouse models for understanding xenobiotic metabolismDocetaxel-loaded liposomes: preparation, pH sensitivity, pharmacokinetics, and tissue distribution.Docetaxel in the treatment of gastric cancer.Cabazitaxel: a new drug for metastatic prostate cancerKnockout of mouse Cyp3a gene enhances synthesis of cholesterol and bile acid in the liver.Resistance to chemotherapy in cancer: a complex and integrated cellular response.Pharmacokinetic-directed dosing of vandetanib and docetaxel in a mouse model of human squamous cell carcinomaLarotaxel: broadening the road with new taxanes.Fulminating septic shock from Clostridium perfringens in an early breast cancer patient with severe myalgia after docetaxel treatment.Phytantriol Based "Stealth" Lyotropic Liquid Crystalline Nanoparticles for Improved Antitumor Efficacy and Reduced Toxicity of Docetaxel.Physiologically based pharmacokinetic model of docetaxel and interspecies scaling: comparison of simple injection with folate receptor-targeting amphiphilic copolymer-modified liposomes.Nanovesicular carrier-based formulation for skin cancer targeting: evaluation of cytotoxicity, intracellular uptake, and preclinical anticancer activity.Enriched variations in TEKT4 and breast cancer resistance to paclitaxel.TROPIC: Phase III trial of cabazitaxel for the treatment of metastatic castration-resistant prostate cancer.Novel therapeutic strategies following docetaxel-based chemotherapy in castration-resistant prostate cancer.Pharmacokinetic evaluation of three oral formulations of docetaxel boosted with ritonavir: two single-drug formulations vs. a fixed-dose combination tablet.In vivo evaluation of cetuximab-conjugated poly(γ-glutamic acid)-docetaxel nanomedicines in EGFR-overexpressing gastric cancer xenografts.Evaluation of in vitro efficacy of docetaxel-loaded calcium carbonate aragonite nanoparticles (DTX-CaCO3NP) on 4T1 mouse breast cancer cell line.Enhanced anti-tumor efficacy and mechanisms associated with docetaxel-piperine combination- in vitro and in vivo investigation using a taxane-resistant prostate cancer model.Fibronectin protects lung cancer cells against docetaxel-induced apoptosis by promoting Src and caspase-8 phosphorylation.A lyophilized sterically stabilized liposome-containing docetaxel: in vitro and in vivo evaluation.Nail toxicity after treatment with docetaxel: a prospective analysis in patients with advanced non-small cell lung cancer.Advancements in the oral delivery of Docetaxel: challenges, current state-of-the-art and future trends.
P2860
Q28540917-985CC2EA-F824-4F4E-9763-1F74BB13A9AFQ30372703-390EE6BB-7944-45BA-B76D-B5818924A865Q33303614-4DBF9D56-1451-48A1-A147-88F05F492CDDQ35523387-7C0BF6C7-6662-4636-BC3B-190CCFABE9E3Q35781409-541B1DF5-752E-4BB3-AD73-4B41B80B52DFQ36099442-B754C54B-EFBC-4B62-BFFD-F7C1C8A80531Q36461825-B5895008-52B7-4135-B726-EF7F63DF3C45Q36616503-D6BF9338-7DF5-4069-AD90-D1ECA20CE5D9Q36670045-CE98E47B-1ECF-4120-AE80-F7FED3E0DE5BQ37002627-8C68F9F4-A404-400F-869A-440D7EDE068EQ37079652-C4EBF061-48BF-42D4-A8D1-8E60E6FB04B3Q37170005-92EE28EA-CCF4-43DB-9869-11A902689F73Q37551909-0E5261E4-DD07-4981-80AF-190A6EEDA5C1Q37694174-88606D1A-5ADA-4E88-8F86-9E03DE518EBEQ38875659-CED5E2D5-E3BD-40CE-82EE-A72D90FA41A7Q38893881-C1FC4D8F-2FFF-473B-A28E-92D634E70FB0Q38938396-3C4182F5-2E29-48EF-9770-671D2EF8F0E5Q38995526-4582EB93-1354-448B-AF1F-B504DE847DDDQ39330552-37051F2E-0233-4948-A9D6-E384F806A71EQ39683668-E2A37E0B-581F-4E0B-B59D-3809A7AB58C3Q41195857-06866D0F-A986-4B44-947E-2E00D2463CA5Q42370589-840F03F6-67AB-4F8A-8321-028BC0C5969DQ46989864-37389CA5-E124-49C8-A51E-FDC5329F061CQ49520967-C4B4968E-4C6B-4D1A-A12D-89ACAA523013Q51611913-4E7D8481-453F-4B8F-836D-2D553B575FE2Q53133237-36834F48-B54F-4203-AAAD-8E5048E5AC36Q53567790-FD44FE32-B969-42CF-87B2-2340FA626CF4Q55278614-ADDCCF6B-4FAE-46F3-B0CB-D679642231CA
P2860
Potential for improvement of docetaxel-based chemotherapy: a pharmacological review.
description
2005 nî lūn-bûn
@nan
2005 թուականի Յուլիսին հրատարակուած գիտական յօդուած
@hyw
2005 թվականի հուլիսին հրատարակված գիտական հոդված
@hy
2005年の論文
@ja
2005年論文
@yue
2005年論文
@zh-hant
2005年論文
@zh-hk
2005年論文
@zh-mo
2005年論文
@zh-tw
2005年论文
@wuu
name
Potential for improvement of docetaxel-based chemotherapy: a pharmacological review.
@ast
Potential for improvement of docetaxel-based chemotherapy: a pharmacological review.
@en
type
label
Potential for improvement of docetaxel-based chemotherapy: a pharmacological review.
@ast
Potential for improvement of docetaxel-based chemotherapy: a pharmacological review.
@en
prefLabel
Potential for improvement of docetaxel-based chemotherapy: a pharmacological review.
@ast
Potential for improvement of docetaxel-based chemotherapy: a pharmacological review.
@en
P2093
P2860
P921
P356
P1476
Potential for improvement of docetaxel-based chemotherapy: a pharmacological review.
@en
P2093
A Sparreboom
F K Engels
R A A Mathot
P2860
P2888
P304
P356
10.1038/SJ.BJC.6602698
P407
P577
2005-07-01T00:00:00Z
2005-07-25T00:00:00Z
P5875
P6179
1021802614